These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 9869598

  • 1. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.
    Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ.
    Gastroenterology; 1999 Jan; 116(1):22-8. PubMed ID: 9869598
    [Abstract] [Full Text] [Related]

  • 2. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.
    D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P.
    Gastroenterology; 1999 May; 116(5):1029-34. PubMed ID: 10220494
    [Abstract] [Full Text] [Related]

  • 3. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.
    Geboes K, Rutgeerts P, Opdenakker G, Olson A, Patel K, Wagner CL, Marano CW.
    Curr Med Res Opin; 2005 Nov; 21(11):1741-54. PubMed ID: 16307694
    [Abstract] [Full Text] [Related]

  • 4. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.
    Di Sabatino A, Ciccocioppo R, Cinque B, Millimaggi D, Morera R, Ricevuti L, Cifone MG, Corazza GR.
    Gut; 2004 Jan; 53(1):70-7. PubMed ID: 14684579
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease.
    Agnholt J, Dahlerup JF, Buntzen S, Tøttrup A, Nielsen SL, Lundorf E.
    Aliment Pharmacol Ther; 2003 Mar 01; 17(5):703-10. PubMed ID: 12641520
    [Abstract] [Full Text] [Related]

  • 13. Infliximab reduces the number of activated mucosal lymphocytes in patients with Crohn's disease.
    Ferkolj I, Ihan A, Markovic S, Veceric Z, Pohar M.
    J Gastrointestin Liver Dis; 2006 Sep 01; 15(3):231-5. PubMed ID: 17013447
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. FOXP3+ regulatory T-cell counts correlate with histological response in Crohn's colitis treated with infliximab.
    Sloan S, Maxwell P, Salto-Tellez M, Loughrey MB.
    Pathol Int; 2014 Dec 01; 64(12):624-7. PubMed ID: 25354875
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.
    Ricciardelli I, Lindley KJ, Londei M, Quaratino S.
    Immunology; 2008 Oct 01; 125(2):178-83. PubMed ID: 18422560
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.